SPAC Drugs Made In America Acquisition II Corp. closes $500M IPO; $500M in trust

Drugs Made In America Acquisition II Corp.

Priced and closed IPO of 50M units at $10/unit for gross proceeds of $500M.
Concurrent private placement of 1.2M units ($12M) to sponsor and Cantor Fitzgerald.
Net proceeds of $500M deposited into trust account for public shareholders.
Units trade on Nasdaq under DMIIU; ordinary shares and rights to trade separately later.
Appointed Catherine Do, G. Sridhar Prasad, Myron W. Shulgan to board and committees.

item 1.01 item 3.02 item 5.02 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Drugs Made In America Acquisition II Corp. issued 1,200,000 units of unit to the Sponsor and Cantor for $10.00 per Private Unit, generating total proceeds of $12,000,000.

Security: unit
Shares: 1,200,000 units
Purchaser: the Sponsor and Cantor
Consideration: $10.00 per Private Unit, generating total proceeds of $12,000,000

Exact text from the filing

Simultaneously with the closing of the IPO, the Company consummated the private placement ("Private Placement") of an aggregate of 1,200,000 units (the "Private Units") to the Sponsor and Cantor, with 700,000 Private Units to the Sponsor and 500,000 Private Units to Cantor, at a price of $10.00 per Private Unit, generating total proceeds of $12,000,000.

View on SEC.gov

Browse all equity issuances →

Drugs Made In America Acquisition II Corp. filing history →

Source: SEC EDGAR

accession 0001213900-25-093224

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.